The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo - Wikidata - wikimedia - TriplyDB

The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo

The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo

http://www.wikidata.org/entity/Q34504770

about

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice HDAC inhibitors as anti-inflammatory agents The many roles of histone deacetylases in development and physiology: implications for disease and therapy HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy HDAC inhibitors and immunotherapy; a double edged sword?Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages Genetics and epigenetics of rheumatoid arthritis Piceatannol Attenuates Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Downregulation of Histone Deacetylase 4/5 or p38-MAPK Signaling Insecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprina Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.IL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity.Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury.Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Un Regulation of lipopolysaccharide-induced inflammatory response and endotoxemia by beta-arrestins Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis Helper T cell plasticity: impact of extrinsic and intrinsic signals on transcriptomes and epigenomes.Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production.Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes.Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).HDAC inhibition and graft versus host disease The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.Augmenting antitumor immune responses with epigenetic modifying agents.Antitumor mechanisms of amino Acid hydroxyurea derivatives in the metastatic colon cancer model.Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8.TNF-α blocker effect of naringenin-loaded sericin microparticles that are potentially useful in the treatment of psoriasis.Potential non-oncological applications of histone deacetylase inhibitors.Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression.

P2860

Q24288997-D678AA68-BEA9-4F5E-865A-F83D1CE65FF3 Q24564962-CC97A615-109B-4CB1-A251-82D7A56AD141 Q24628821-B11AD678-9D5D-4C09-A642-C3FD00BCE3C9 Q26739120-25FCB03A-8501-4BF0-8216-EB521E8F41E6 Q26768497-9C0C1A71-F8DE-4144-B2A8-D4341B20D1B8 Q26783032-36F1F0EC-E66F-45F5-BD24-05AE81A0B136 Q26853102-E118E2DB-7338-42EE-BF06-A868408482AA Q28076052-B31F4A71-91E1-4726-943D-0752964885F5 Q28294510-FD81165E-DE29-46BB-9287-65BE9A53CC9C Q28534348-11798363-5C00-429A-9D9D-3CBE731192AB Q28554628-1D0DEA8C-CB51-401B-8C7F-0EC81123CC29 Q28818731-3ECEA938-DD0C-4568-B4A7-CD628331E05D Q30251920-32F3635C-9490-414B-9BC0-393D7F8E3C52 Q30666883-37B02318-9E52-4C32-BE72-E50CDF91909F Q33336612-6CA208A9-8FAF-49F2-8990-6BB2CF3901FA Q33613257-668F874D-68FE-452D-8EAA-983AA871969C Q33632244-4D0BEAE1-8923-4AF8-81D6-F5CF7B4984FD Q33869272-E06DE63F-8F22-4D6E-8BFA-888D88DC6B6F Q33998649-D8D4FCD8-38DB-4538-86CF-E9C915C99077 Q34048411-6E779353-91F5-4649-A156-C2465AB48DA1 Q34091848-33F22BDB-1E2B-48C6-B215-CF742FED4BD1 Q34152949-9087F292-870E-4BFE-8994-E2B4A4D254FA Q34356521-C4FEDBD1-0F87-40FA-805C-F3A66C44A2DB Q34635234-488DE81F-809E-4ADD-8559-7FFDC497BEDB Q34640790-355ABB7B-2887-4198-9AE9-1272FEFA03E6 Q34739990-27433F5F-1401-4F16-86D9-2EF4337BFD1B Q34988095-FD20ED71-1A0C-4FE6-909A-C57EC2CCB926 Q35002986-FEA1175E-561C-42FF-AA3A-4D980CA819BF Q35016934-C5EC16FE-A208-45B3-B2C2-3213B559A3CD Q35016951-695B6C8F-F1E2-479B-8407-ECDEBB8B793E Q35016969-39D1D541-DEE0-4351-AF46-FDF715524B3E Q35016985-A2E6ED23-17C1-415F-A3E0-F9522A621F5B Q35016997-3834DA33-9B88-4AFC-9C46-ECD5127B3B80 Q35017018-689CE9E9-F979-47C7-8C61-84F899A88229 Q35048054-E6BE2CC4-6FBA-4998-912F-13461931BCA6 Q35058878-790E8D12-12CD-4372-B53B-351D64A0BD13 Q35134756-ACBD498E-85DC-4D58-96E6-70EB3139004F Q35220914-52F01F0F-701D-4B72-A6B4-C1FCCE1D7CE5 Q35485587-FF2E7AA3-4900-42D4-BE08-EECE8A34033E Q35599579-0E062364-E099-4266-9147-42C04DF424D5

P2860

The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo

http://www.wikidata.org/entity/Q34504770

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

The histone deacetylase inhibi ...... systemic inflammation in vivo

@ast

The histone deacetylase inhibi ...... systemic inflammation in vivo

@en

The histone deacetylase inhibi ...... systemic inflammation in vivo

@nl

type

label

The histone deacetylase inhibi ...... systemic inflammation in vivo

@ast

The histone deacetylase inhibi ...... systemic inflammation in vivo

@en

The histone deacetylase inhibi ...... systemic inflammation in vivo

@nl

prefLabel

The histone deacetylase inhibi ...... systemic inflammation in vivo

@ast

The histone deacetylase inhibi ...... systemic inflammation in vivo

@en

The histone deacetylase inhibi ...... systemic inflammation in vivo

@nl

P1433

Q34504770-78407F9E-C401-4325-ACEB-BBE4EFC42B50

P1476

Q34504770-8E88B9A4-BD7B-478D-A616-8395A87845F4

P2093

Q34504770-02F3960A-DB86-47B9-8B78-6A98078297A2

Q34504770-0C306937-6A70-462C-851D-151B807C2A99

Q34504770-17399054-3E8E-4A1C-98D3-E240197E2120

Q34504770-2D2C0AEF-B139-4664-A8DF-F19E38AA4E54

Q34504770-3AE06605-1EDC-4A8B-917B-9D294CA85683

Q34504770-3E0C4500-7161-46B5-942A-DBCED0902859

Q34504770-42FD1320-597B-400D-A2D7-1A3C7EBF4A86

Q34504770-5BC82AE5-0651-4852-BA96-0647486D2173

Q34504770-6C899368-0032-439A-ACCD-5AB962717B35

Q34504770-97A5D8EE-7C58-4A46-9963-04B9C35412B1

P2860

Q34504770-0625E314-CAD7-4B28-88FF-8CB2C08955C3

Q34504770-093E7D89-1A7C-4ED0-9443-E0D0A4A0961B

Q34504770-0F9D9BD6-B4B9-4429-923C-C46D5161838A

Q34504770-188C36CD-2EBD-4EEB-92A7-1F6CE87A6CDF

Q34504770-2693CAA5-5579-4900-BB69-4760536A10BC

Q34504770-296953CD-6252-4947-926E-1939147514C3

Q34504770-332548CA-9F1B-46AD-882D-587DD6C65996

Q34504770-35D187A9-CBD8-4C03-B203-56239C5B58CB

Q34504770-387EB2ED-7B27-4D45-9B59-F522DDE6AD2E

Q34504770-3F80DA9B-DF1B-4A2D-B177-B24CE8E9D326

P2888

Q34504770-37116805-5BAC-4E6A-88F3-025DA8759570

P304

Q34504770-E7869B53-7625-4BD5-AEBF-AAE64963DAFB

P31

Q34504770-3B181AFE-E065-4D6D-B0ED-2DE5D7E5D2C0

P356

Q34504770-21B206CA-C460-4A15-BCC3-042EA0E7836B

P407

Q34504770-61262F99-1106-4212-BD6F-0C3448AD07B1

P433

Q34504770-91EAE6BE-C37C-4CDA-AAC7-F71CDCA7555E

P478

Q34504770-34894D17-A2A5-4600-9D69-A192ECB0DCD3

P50

Q34504770-F1814198-068D-44FC-A54F-891852DF1DCF

P577

Q34504770-5350AAC3-077A-47AE-9073-C097C6AAAF02

P6179

Q34504770-3BF82041-5FC2-42D1-816A-466BF57E59DB

P698

Q34504770-F43152C3-1653-49F4-86F1-62EF13B95808

P932

Q34504770-567F51AA-D5CF-4E09-9AC3-3892033780C1

P356

2006-00005.DINARELLO

P1433

Molecular Medicine

P1476

The histone deacetylase inhibi ...... systemic inflammation in vivo

@en

P2093

Britta Siegmund

http://www.w3.org/2001/XMLSchema#string

Daniela Modena

http://www.w3.org/2001/XMLSchema#string

Eli C Lewis

http://www.w3.org/2001/XMLSchema#string

Flavio Leoni

http://www.w3.org/2001/XMLSchema#string

Giamila Fantuzzi

http://www.w3.org/2001/XMLSchema#string

Gianluca Fossati

http://www.w3.org/2001/XMLSchema#string

Giulia Porro

http://www.w3.org/2001/XMLSchema#string

Jae-Kwon Lee

http://www.w3.org/2001/XMLSchema#string

Leonid L Reznikov

http://www.w3.org/2001/XMLSchema#string

Maria Lusia Moras

http://www.w3.org/2001/XMLSchema#string

P2860

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

Identification of a locus on chromosome 1q44 for familial cold urticaria.

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65

Duration of nuclear NF-kappaB action regulated by reversible acetylation

A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes

P2888

2006-00005.dinarello

P304

1-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2119/2006-00005.DINARELLO

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-12

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Charles A. Dinarello

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1068964917

http://www.w3.org/2001/XMLSchema#string

P698

16557334

http://www.w3.org/2001/XMLSchema#string

P932

1449516

http://www.w3.org/2001/XMLSchema#string